Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Abstract Background Immune-checkpoint inhibitors plus chemotherapy are emerging as effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), but little is known about the magnitude of benefits and potential clinical predictors. Methods We performed a meta-analysis of randomiz...

Full description

Bibliographic Details
Main Authors: Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitor
Programmed death 1
Programmed death 1 ligand 1
Chemotherapy
Non-small cell lung carcinoma
Predict
Online Access:http://link.springer.com/article/10.1186/s40425-018-0477-9

Internet

http://link.springer.com/article/10.1186/s40425-018-0477-9

Similar Items